Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
Status:
Recruiting
Trial end date:
2031-04-30
Target enrollment:
Participant gender:
Summary
This is a phase 2 study investigating the efficacy of ramucirumab in combination with
pembrolizumab compared to pembrolizumab monotherapy. Ramucirumab is a VEGFR-2 inhibitor
believed to potentially enhance the efficacy of PD-1 inhibitors such as pembrolizumab.